Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women
Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women
复制标题
DOI：
10.1007/s00774-013-0472-7
复制
发表时间：
2014-03-01
影响因子：
3.3
通讯作者：
Ishimi, Yoshiko
中科院分区：
文献类型：
--
作者：
Koitaya, Noriko;Sekiguchi, Mariko;Ishimi, Yoshiko
甲萘醌-4（MK-4）以45 mg/天的药理学剂量给药已在日本用于治疗骨质疏松症。然而，目前尚不清楚较低剂量的MK-4补充剂是否有益于健康绝经后妇女的骨骼健康。本研究的目的是检查1.5毫克的MK-4补充剂对骨转换和骨矿物质密度（BMD）的各种标志物的长期影响。本研究是一项随机、双盲、安慰剂对照试验。参与者（年龄50-65岁）根据接受的MK-4剂量被随机分配到两组之一：安慰剂对照组（n = 24）和1.5 mg MK-4组（n = 24）。两组中未充分羧化骨钙素（ucOC）的基线浓度均较高（> 5.1 ng/ml）。6个月和12个月后，MK-4组的血清ucOC浓度显著低于对照组。在对照组中，血清戊糖苷浓度无显著变化。然而，在MK-4组中，6个月和12个月时的戊糖苷浓度显著低于基线水平。对照组术后12个月前臂骨密度明显低于术后6个月。然而，在研究期间，MK-4组的BMD没有显著降低。这些结果表明，低剂量MK-4补充6-12个月通过降低血清ucOC和戊糖苷浓度改善了绝经后日本女性的骨质量，而没有任何实质性的不良反应。
Menaquinone-4 (MK-4) administered at a pharmacological dosage of 45 mg/day has been used for the treatment of osteoporosis in Japan. However, it is not known whether a lower dose of MK-4 supplementation is beneficial for bone health in healthy postmenopausal women. The aim of this study was to examine the long-term effects of 1.5-mg daily supplementation of MK-4 on the various markers of bone turnover and bone mineral density (BMD). The study was performed as a randomized, double-blind, placebo-controlled trial. The participants (aged 50-65 years) were randomly assigned to one of two groups according to the MK-4 dose received: the placebo-control group (n = 24) and the 1.5-mg MK-4 group (n = 24). The baseline concentrations of undercarboxylated osteocalcin (ucOC) were high in both groups (> 5.1 ng/ml). After 6 and 12 months, the serum ucOC concentrations were significantly lower in the MK-4 group than in the control group. In the control group, there was no significant change in serum pentosidine concentrations. However, in the MK-4 group, the concentration of pentosidine at 6 and 12 months was significantly lower than that at baseline. The forearm BMD was significantly lower after 12 months than at 6 months in the control group. However, there was no significant decrease in BMD in the MK-4 group during the study period. These results suggest that low-dose MK-4 supplementation for 6-12 months improved bone quality in the postmenopausal Japanese women by decreasing the serum ucOC and pentosidine concentrations, without any substantial adverse effects.